SCHEMBL6779110

SCHEMBL6779110

NC1CC(=O)Sc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 3/20 0.36
GRM1 Q13255 3/20 0.35
GRM5 P41594 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
S100A4 P26447 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
HTR2A P28223 1/20 0.32
CYP2D6 P10635 1/20 0.32
AADAT Q8N5Z0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9693133 0.77 HTR2A (0.45) ANPEPALDH1A1TP53CYP3A4MAPT
SCHEMBL88255 0.68 HTR2A (0.46) ANPEPGRM1GRM5GAAMEN1
SCHEMBL8144693 0.67 HTR2A (0.41) ANPEPALDH1A1GAAMEN1MAPT
SCHEMBL15129175 0.65 S100A4 (0.53) ANPEPALDH1A1S100A4KDM4EMEN1
SCHEMBL1989836 0.65 S100A4 (0.53) ANPEPALDH1A1S100A4KDM4EMEN1
SCHEMBL14855914 0.65 S100A4 (0.53) ANPEPALDH1A1S100A4KDM4EMEN1
SCHEMBL6783782 0.65 ANPEP (0.47) ANPEPALDH1A1KDM4EMEN1MAPT
SCHEMBL24399522 0.64 S100A4 (0.52) ANPEPALDH1A1S100A4KDM4EMEN1
SCHEMBL1265766 0.64 USP2 (0.45) MEN1KMT2A
SCHEMBL5255020 0.64 USP2 (0.45) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed